Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

NCT05275205 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: UBX1325 injection 50 μL
DRUG: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Sponsor

Unity Biotechnology, Inc.